HEALTH CATALYST, INC. (HCAT): Price and Financial Metrics
GET POWR RATINGS... FREE!
HCAT POWR Grades
- Growth is the dimension where HCAT ranks best; there it ranks ahead of 69.64% of US stocks.
- HCAT's strongest trending metric is Stability; it's been moving down over the last 179 days.
- HCAT ranks lowest in Quality; there it ranks in the 14th percentile.
HCAT Stock Summary
- HCAT's went public 3.32 years ago, making it older than merely 16.69% of listed US stocks we're tracking.
- With a year-over-year growth in debt of 22.82%, HEALTH CATALYST INC's debt growth rate surpasses 70.56% of about US stocks.
- In terms of volatility of its share price, HCAT is more volatile than 89.24% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to HEALTH CATALYST INC, a group of peers worth examining would be LYFT, AMPL, AFRM, PD, and DOMO.
- HCAT's SEC filings can be seen here. And to visit HEALTH CATALYST INC's official web site, go to www.healthcatalyst.com.
HCAT Valuation Summary
- In comparison to the median Technology stock, HCAT's price/sales ratio is 16.67% lower, now standing at 2.
- Over the past 40 months, HCAT's price/sales ratio has gone down 7.7.
Below are key valuation metrics over time for HCAT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| HCAT | 2022-11-14 | 2.0 | 1.2 | -3.6 | -4.5 |
| HCAT | 2022-11-11 | 2.0 | 1.2 | -3.6 | -4.5 |
| HCAT | 2022-11-10 | 1.8 | 1.1 | -3.3 | -4.2 |
| HCAT | 2022-11-09 | 1.6 | 1.0 | -2.9 | -3.8 |
| HCAT | 2022-11-08 | 1.3 | 0.8 | -2.4 | -2.9 |
| HCAT | 2022-11-07 | 1.4 | 0.8 | -2.6 | -3.1 |
HCAT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- HCAT has a Quality Grade of D, ranking ahead of 6.31% of graded US stocks.
- HCAT's asset turnover comes in at 0.378 -- ranking 389th of 561 Business Services stocks.
- 500 - Internal server error
The table below shows HCAT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.378 | 0.499 | -0.456 |
| 2021-03-31 | 0.365 | 0.492 | -0.321 |
| 2020-12-31 | 0.393 | 0.481 | -0.299 |
| 2020-09-30 | 0.435 | 0.479 | -0.249 |
| 2020-06-30 | 0.490 | 0.489 | -0.269 |
| 2020-03-31 | 0.616 | 0.502 | -0.314 |
HCAT Price Target
For more insight on analysts targets of HCAT, see our HCAT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $66.00 | Average Broker Recommendation | 1.23 (Strong Buy) |
HCAT Stock Price Chart Interactive Chart >
HCAT Price/Volume Stats
| Current price | $9.78 | 52-week high | $44.53 |
| Prev. close | $9.98 | 52-week low | $6.40 |
| Day low | $9.54 | Volume | 258,700 |
| Day high | $10.03 | Avg. volume | 947,128 |
| 50-day MA | $9.32 | Dividend yield | N/A |
| 200-day MA | $15.86 | Market Cap | 535.46M |
HEALTH CATALYST, INC. (HCAT) Company Bio
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services. The company is headquartered in Salt Lake City, Utah.
Latest HCAT News From Around the Web
Below are the latest news stories about HEALTH CATALYST INC that investors may wish to consider to help them evaluate HCAT as an investment opportunity.
CEO & Director Daniel Burton Just Bought 42% More Shares In Health Catalyst, Inc. (NASDAQ:HCAT)Those following along with Health Catalyst, Inc. ( NASDAQ:HCAT ) will no doubt be intrigued by the recent purchase of... |
Health Catalyst Third Quarter 2022 Earnings: US$0.84 loss per share (vs US$0.82 loss in 3Q 2021)Health Catalyst ( NASDAQ:HCAT ) Third Quarter 2022 Results Key Financial Results Revenue: US$68.4m (up 11% from 3Q... |
Here’s Why Health Catalyst Stock (NASDAQ: HCAT) Surged Almost 30% TodayShares of Health Catalyst (NASDAQ: HCAT) surged almost 30% in today's session after it reported earnings for its third quarter of Fiscal Year 2022. Adjusted earnings per share came in at -$0.13, which beat analysts' consensus estimate of -$0.19 per share. Sales increased 10.72% year-over-year, with revenue hitting $68.35 million. This beat analysts' target by $1.56 million. Looking forward, management is expecting revenue for Q4 2022 to be in the range of $66.9 million to $68.9 million. For reference, analysts were expecting $66.79 million. |
Why Shares of Health Catalyst Popped 23.34% on WednesdayShares of Health Catalyst (NASDAQ: HCAT), jumped 23.34% on Wednesday. The company, which provides data and analytic solutions to healthcare companies, released its third-quarter earnings after the market closed on Tuesday. The company reported revenue of $68.4 million, up 11%, year over year, led by a 15% jump in revenue from its technology segment. |
Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue EstimatesHealth Catalyst (HCAT) delivered earnings and revenue surprises of 35% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
HCAT Price Returns
| 1-mo | 8.55% |
| 3-mo | -18.77% |
| 6-mo | N/A |
| 1-year | -77.58% |
| 3-year | -73.91% |
| 5-year | N/A |
| YTD | -75.32% |
| 2021 | -8.98% |
| 2020 | 25.45% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...